AI intelligence is not yet available for WellDyneRx. The portfolio data below is up to date.
1 app analysed
Direct pharmacy benefit management integration
0
Positive apps
1
Neutral / mixed
0
Negative apps
50/100
Avg sentiment score
Strategic outlook coming soon.
Portfolio
Free 1Last updated
WellView
v12.3.7
1mo ago
Single-market publisher — every app ships only to United States.
Based on 1 of 1 app with localized market data · last scanned .
Shotsy directly competes for the GLP-1 user base by providing specialized medication tracking and scheduling that overlaps with WellView's pharmacy management utility.
This app is a broad-spectrum medication management tool that overlaps with WellView's core prescription tracking and reminder functionality.
This app targets the same GLP-1 patient demographic by focusing on the clinical side of medication management, specifically injection logging and side effects.
Stelo competes by providing biosensor-driven health insights, positioning itself as a premium alternative for glucose monitoring.
A new entrant specifically targeting the GLP-1 medication market with modern AI-driven insights.
This app competes on the core utility of medication adherence and inventory management, directly challenging WellView's prescription management features.
Cuspart competes by offering professional-grade reporting and data logging, appealing to users who need clinical documentation for their medical providers.
This app provides specialized hardware-integrated monitoring for diabetes management, overlapping with the health-tracking needs of WellView users.
This app serves the same chronic condition management market, focusing on blood sugar tracking and real-time data visualization.
A new medical-focused app that brings advanced pharmacokinetic modeling to the consumer mobile space.